Qiming Venture Partners Portfolio Companies Named Beijing Digital Economy Benchmark Enterprises
Benchmark enterprises not only drive core growth but also demonstrate and catalyze the shared development of upstream and downstream partners, advancing high-quality growth in the digital economy.
Recently, the 2024 Beijing Digital Economy Benchmark Enterprises Evaluation Report was officially released at a thematic forum of the 2025 Global Digital Economy Conference — the 2025 Industrial Internet Innovation and Development Forum. The selected benchmark enterprises not only contribute core growth momentum but also demonstrate and drive the collective growth of industrial chain enterprises, advancing high-quality development of the digital economy.
Portfolio companies of Qiming Venture Partners including Xiaomi (01810.HK), XSKY, Zhipu AI, Roborock (688169.SH), Shukun Technology, Yuanxin Technology, and DeepWise were among those selected.
Xiaomi, XSKY, Zhipu AI
(Digital Infrastructure Technology)
Roborock, Shukun Technology
(Digital Empowerment)
Yuanxin Technology
(Digital Platforms)
DeepWise and others
(New Models and New Applications)
Selected for the
2024 Beijing Digital Economy Benchmark Enterprises Evaluation Report
2024 Beijing Digital Economy Benchmark Enterprises Evaluation
The report drew on the 2023 benchmark enterprise reserve pool and recommended list to form an enterprise reserve pool. Following the group standard Beijing Digital Economy Benchmark Enterprises Evaluation Specifications, it adopted an evaluation model combining "general indicators + personalized indicators" to select enterprises. An expert panel shortlisted 100 benchmark enterprises, covering four categories: digital infrastructure technology, digital platforms, digital empowerment, and new models and new applications.
The 2024 Beijing Digital Economy Benchmark Enterprises Evaluation Report shows that digital infrastructure technology benchmark enterprises' main businesses cover foundational software, computer manufacturing, integrated circuit design, artificial intelligence, cloud computing, and more. Digital empowerment benchmark enterprises' businesses cover application software development, smart finance, and intelligent manufacturing. Digital platform benchmark enterprises' businesses concentrate on other internet-related services. New models and new applications benchmark enterprises' businesses focus primarily on innovative fields such as artificial intelligence.
Source | Global Digital Economy Conference
Past Coverage
Qiming Stars | Multiple Qiming Venture Partners Portfolio Companies Selected as Typical Cases for AI Large Model Scenario Applications Speaker Lineup Revealed | Register Now for 2025 WAIC Qiming Venture Partners · Entrepreneurship and Investment Forum — Venture Capital Enters a Resonance Cycle of AI Technology and Applications Agenda Premiere | 2025 WAIC Qiming Venture Partners · Entrepreneurship and Investment Forum — Venture Capital Enters a Resonance Cycle of AI Technology and Applications
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage enterprises in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.